Первая клетка. И чего стоит борьба с раком до последнего - Азра Раза

That? Dr. Vinay Prasad Takes on Big Pharma, Big Medicine, and His Own Colleagues – With Glee. Stat, September 15, 2017.

Exceptional Responders: Why Do Some Cancer Drugs Work for Them and Not Others? Cancer Treatment Centers of America, March 8, 2018. www.cancercenter.com/community/blog/2018/03/why-do-some-cancer-drugs-work-for-them-and-not-others

Milowsky M. I. et al. Phase II Study of Everolimus in Metastatic Urothelial Cancer. BJU International. 112, no. 4 (2013): 462–470.

NCI Sponsored Trials in Precision Medicine. Division of Cancer Treatment and Diagnosis. https://dctd.cancer.gov/majorinitiatives/NCI-sponsored_trials_in_precision_medicine.htm

West H. Novel Precision Medicine Trial Designs Umbrellas and Baskets. JAMA Oncology. 3, no. 3 (2017): 423.

Marquart J. et al. Estimation of the Percentage of US Patients with Cancer Who Benefit from Genome-Driven Oncology. JAMA Oncology. 4, no. 8 (2018): 1093–1098.

Prasad V. Perspective: The Precision-Oncology Illusion. Nature. 537 (2016): S63.

Kaiser J. A Cancer Drug Tailored to Your Tumor? Experts Trade Barbs over “Precision Oncology”. Science, April 24, 2018. doi:10.1126/science.aat9794.

Harris L. et al. Update on the NCI—Molecular Analysis for Therapy Choice (NCI—MATCH/EAY131) Precision Medicine Trial. Pharmacogenetics, Pharmacogenomics, and Therapeutic Response. 17, supplement 1 (2018). doi:10.1158/1535–7163. TARG-17-B080.

Davis C. et al. Availability of Evidence of Benefits on Overall Survival and Quality of Life of Cancer Drugs Approved by European Medicines Agency: Retrospective Cohort Study of Drug Approvals, 2009–13. BMJ. 359 (2017). doi:10.1136/bmj.j4530.

Drilon A. et al. Efficacy of Larotrectinib in TRK Fusion – Positive Cancers in Adults and Children. New England Journal of Medicine. 378 (2018): 731–739.

Broderick J. M. FDA Approves Larotrectinib for NTRK + Cancers. OncLive, November 26, 2018. www.onclive.com/view/fda-approves-larotrectinib-for-ntrk-cancers

Darwin Ch. On the Origin of Species. Digireads.com. [Дарвин Ч. Происхождение видов путем естественного отбора, или Сохранение благоприятных рас в борьбе за жизнь. СПб.: Наука, 1991.]

Nowell P. C. The Clonal Evolution of Tumor Cell Populations. Science. 194, no. 4260 (1976): 23–28.

Greaves M., Maley C. C. Clonal Evolution in Cancer. Nature. 481 (2012): 306–313.

Janiszewska M. et al. Clonal Evolution in Cancer: A Tale of Twisted Twines. Cell Stem Cell. 16 (2015). doi:10.1016/j.stem.2014.12.011.

McGranahan N., Swanton Ch. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell. 168, no. 4 (2017): 613–628.

Fidler I. J. The Pathogenesis of Cancer Metastasis: The ‘Seed and Soil’ Hypothesis Revisited. Nature Reviews Cancer. 3 (2003): 453–458.

Ribatti D. et al. Stephen Paget and the ‘Seed and Soil’ Theory of Metastatic Dissemination. Clinical and Experimental Medicine. 6, no. 4 (2006): 145–149.

Fidler I. J. et al. The ‘Seed and Soil’ Hypothesis Revisited. Lancet Oncology. 9, no. 8 (2008): 808.

Pienta K. et al. The Cancer Diaspora: Metastasis Beyond the Seed and Soil Hypothesis. Clinical Cancer Research. 19, no. 21 (2013). doi:10.1158/1078–0432. CCR-13–2158.

Tiong Ing S. et al. New Drugs Creating New Challenges in Acute Myeloid Leukemia. Genes, Chromosomes & Cancer. (2019). doi:10.1002/gcc.22750.

Kubal T. E. et al. Safety and Feasibility of Outpatient Induction Chemotherapy with CPX-351 in Selected Older Adult Patients with Newly Diagnosed AML. Journal of Clinical Oncology. 36, supplement 15 (2018): e19013.

Levis M. Midostaurin Approved for FLT3-Mutated AML. Blood. 129 (2017): 3403–3406.

Глава 4. Китти С

Profiles in Science. The Mary Lasker papers. US National Library of Medicine.

Wallace L. G. Catalyst for the National Cancer Act: Mary Lasker. Albert and Mary Lasker Foundation. December 15, 2016. https://laskerfoundation.org/catalyst-for-the-national-cancer-act-mary-lasker/

National Cancer Act of 1971. National Cancer Institute. https://dtp.cancer.gov/timeline/noflash/milestones/M4_Nixon.htm

Holford T. R. Tobacco Control and the Reduction in Smoking-Related Premature Deaths in the United States, 1964–2012. JAMA. 311, no. 2 (2014): 164–171.

Kolata G. Advances Elusive in the Drive to Cure Cancer. New York Times, April 23, 2009.

Leaf C. The Truth in Small Doses: Why We’re Losing the War on Cancer – And How to Win. New York: Simon & Schuster, 2013.

Baker M. 1,500 Scientists Lift the Lid on Reproducibility: Survey Sheds Light on the ‘Crisis’ Rocking Research. Nature. 533 (2016): 452–454.

DeVita V. T., Jr., Chu E. A History of Cancer Chemotherapy. Cancer Research. 68, no. 21 (2008). doi:10.1158/0008–5472.CAN-07–6611.

Gilligan A. M. Death or Debt? National Estimates of Financial Toxicity in Persons with Newly-Diagnosed Cancer. American Journal of Medicine. 131, no. 10 (2018): 1187–1199.

Fojo T. et al. Unintended Consequences of Expensive Cancer Therapeutics – The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity: The John Conley Lecture. JAMA Otolaryngology – Head & Neck Surgery. 140, no. 12 (2014): 1225–1236.

Marchetti S., Schellens J. H. M. The Impact of FDA and EMEA Guidelines on Drug Development in Relation to Phase 0 Trials. British Journal of Cancer. 97 (2007): 577–581.

Kummar Sh. Compressing Drug Development Timelines in Oncology Using Phase ‘0’ Trials. Nature Reviews Cancer. 7 (2007): 131–139.

Murgo J. A. et al. Designing Phase 0 Cancer Clinical Trials. Clinical Cancer Research. 14, no. 12 (2008).

Spector R. The War on Cancer: A Progress Report for Skeptics. Skeptical Inquirer, January/February 2010.

Hitchens Ch. Topic of Cancer. Vanity Fair, August 2010.

Adams C. P., Brantner V. V. Estimating the Cost of New Drug Development: Is It Really 802 Million Dollars? Health Affairs (Millwood). 25, no. 2 (2006): 420–428.

Глава 5. Джей-Си

Donor Registry Data. US Department of Health and Human Services. https://bloodcell.transplant.hrsa.gov/research/registry_donor_data/index.html

Koutsavlis I. Transfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic Syndromes. Anemia, 2016. doi:10.1155/2016/8494738.

Black Bone Marrow.com. http://blackbonemarrow.com/

Poynter J. N. et al. Chemical Exposures and Risk of Acute Myeloid Leukemia and Myelodysplastic Syndromes in a Population-Based Study. International Journal of Cancer. 140, no. 1 (2017): 23–33.

Murphy T., Yee K. W. L. Cytarabine and Daunorubicin for the Treatment of Acute Myeloid Leukemia. Expert Opinion on Pharmacotherapy. 18, no. 16 (2017): 1765–1780.

Steele J. The Man Who Would Tame Cancer: Patrick Soon-Shiong Is Opening a New Front in the War on the Deadly Disease. Nautilus, January 28, 2016.

Raza A. et al. Apoptosis in Bone Marrow Biopsy Samples Involving Stromal and Hematopoietic Cells in 50 Patients with Myelodysplastic Syndromes. Blood. 86, no. 1 (1995): 268–276.

Raza A. et al. Novel Insights into the Biology of Myelodysplastic Syndromes: Excessive Apoptosis and the Role of Cytokines. International Journal of Hematology. 63, no. 4 (1996): 265–278.

Raza A. et al. Thalidomide Produces Transfusion Independence in Long Standing Refractory Anemias of Patients with Myelodysplastic Syndromes. Blood. 98, no. 4 (2001): 958–965.

Raza A., Galili N. The Genetic Basis of Phenotypic Heterogeneity in Myelodysplastic Syndromes. Nature Reviews Cancer. 12, no. 12 (2012): 849–859.

Глава 6. Андрей

Wen P. Y., Kesari S. Malignant Gliomas in Adults. New England Journal of Medicine. 359 (2008): 492–507.

Stewart L. A. Chemotherapy in Adult High-Grade Glioma: A Systematic Review and Meta-Analysis of Individual Patient Data from 12 Randomised Trials. Lancet. 359 (2002): 1011–1018.

KÜbler-Ross E. On Death and Dying. New York: Scribner, 1997.

[Кюблер-Росс Э. О смерти и умирании. СПб: Корвет, 2016.]

Izard J., Siemens D. R. What’s in Your Toolkit? Guiding Our Patients Through Their Shared Decision-Making. Canadian Urological Association Journal. 12, no. 10 (2018): 294–295.

Hagedoorn M. et al. Coping with Cancer: The Perspective of Patients’ Relatives. Acta Oncologica. 50, no. 2 (2011): 205–211.

Wohlfarth P. et al. Chimeric Antigen Receptor T-Cell Therapy – A Hematological Success Story. Memo. 11, no. 2 (2018): 116–121.

Titov A. et al. The Biological Basis and Clinical Symptoms of CAR-T Therapy-Associated Toxicities. Cell Death & Disease. 9 (2018): article 897.

Fried Sh. et al. Early and Late Hematologic Toxicity Following CD19 CAR-T Cells. Bone Marrow Transplantation, 2019. doi:10.1038/s41409-019-0487-3.

Brudno J. N., Kochenderfer J. N. Chimeric Antigen Receptor T-Cell Therapies for Lymphoma. Nature Reviews Clinical Oncology. 15 (2018): 31–46.

Mahadeo K. M. Management